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Introduction {#sec001}
============

*Enterococcus faecalis* is the third most common cause of infective endocarditis (IE) \[[@pone.0237011.ref001]\]. *E*. *faecalis* infective endocarditis (EFIE) is characterized by its increasing incidence and tendency to affect elderly patients and those with multiple comorbidities \[[@pone.0237011.ref002], [@pone.0237011.ref003]\].

*E*. *faecalis* is remarkably resistant to antibiotic-induced eradication, which requires treatment with synergistic antibiotic combinations. Currently, the combination of ampicillin plus ceftriaxone (AC) is the antibiotic treatment of choice for EFIE in several settings, and especially so in Spain \[[@pone.0237011.ref004]--[@pone.0237011.ref007]\]. With respect to treatment duration, international guidelines recommend a 6 week-course of AC for native valve EFIE \[[@pone.0237011.ref008], [@pone.0237011.ref009]\]. However, these same guidelines accept the use of other antibiotic combinations (e.g. a beta-lactam plus gentamicin) for four weeks when the duration of symptoms is shorter than 3 months. Evidence is lacking from studies comparing the efficacy of shorter courses of AC with respect to the recommended duration of 6 weeks for the treatment of EFIE. However, the use of a shortened course of AC is relatively common for treating non-complicated native EFIE.

The aim of the present study was to analyze whether the clinical outcomes of patients suffering from native valve EFIE treated with a short-course regimen of AC (four weeks) were similar to those of patients treated for the recommended six weeks.

Methods {#sec002}
=======

Between January 2008 and June 2018, 3,830 consecutive patients were prospectively included in the "Spanish Collaboration on Endocarditis---Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES)", a registry maintained by 27 Spanish hospitals. Multidisciplinary teams completed standardized case report forms with IE episode and follow-up data that included clinical, microbiological and echocardiographic sections \[[@pone.0237011.ref010], [@pone.0237011.ref011]\]. The study was approved by regional ethics committee (Comité Ético de Investigación Clínica Regional de la Comunidad de Madrid with approval code: 07/18). Written informed consent was obtained from all patients.

Definitions {#sec003}
-----------

IE was defined according to the modified Duke criteria \[[@pone.0237011.ref012]\]. Microbiological diagnoses were determined by blood or valve culture and/or molecular techniques \[[@pone.0237011.ref010]\]. Transthoracic (TTE) and transesophageal echocardiography (TEE) were performed on patients with clinical or microbiological suspicion of IE according to European guidelines, or to diagnose valve dysfunction and intracardiac complications such as abscess, vegetation, pseudoaneurysm and fistula \[[@pone.0237011.ref008], [@pone.0237011.ref013], [@pone.0237011.ref014]\]. Hospital-acquired IE was defined as either IE manifesting \>48 hours after hospital admission or IE acquired in association with a significant invasive procedure performed within 6 months prior to diagnosis. The EuroScore and LogEuroScore were used to assess surgical risk \[[@pone.0237011.ref015]\]. All the necessary variables were collected to calculate the Charlson Comorbidity Index \[[@pone.0237011.ref016]\].

For the purposes of this study, patients with definite native valve EFIE were selected from the GAMES database. Patients who only met possible Duke IE criteria as well as right-sided IE cases without concomitant left-side infection were excluded from the study. Fourteen patients had been included in a previous investigation \[[@pone.0237011.ref017]\]. Patients classified as treated with AC did not receive gentamicin at any time. The dose of ampicillin was 12 grams per day in 4 or 6 doses (adjusted for renal function) and ceftriaxone was 2 g every 12 hours, both intravenously. The decision about the duration of treatment was taken by the responsible physicians at the beginning of the treatment but could also be taken during the patient\'s clinical evolution. Patients were classified according to the length of treatment: patients who received 28 ± 4 days of AC antibiotic treatment were included in the short-course group, whereas patients who received 42 ± 6 days of treatment were included in the long- or conventional-treatment group The date of the first negative blood culture was considered in calculating the duration of treatment. Patients with a length of treatment that did not fit any of these definitions were excluded.

In-hospital mortality was defined as death, irrespective of cause, that occurred during hospital admission in patients who had completed antibiotic treatment. Patients who died before completing their allotted course of treatment were excluded from the analysis. The Cockcroft-Gault equation was used to calculate creatinine clearance \[[@pone.0237011.ref018]\]. Pre-episode renal insufficiency was defined as plasma creatinine over 1.4 mg/dl. New or worsening renal insufficiency during the IE episode was defined as an increase of baseline creatinine clearance or plasma creatinine by at least 25%, or creatinine levels over 1.4 mg/dl when a previous analysis had been normal. Persistent bacteremia was defined as positive blood cultures more than seven days after effective antibiotic therapy. Endocarditis relapse was defined a new episode of EFIE during the first year after finishing treatment.

Data from patients with native valve EFIE were analyzed, including clinical manifestations at IE presentation, pathogens, therapy, morbidity and mortality during hospitalization and during the first year after hospitalization. Follow-up information was obtained via programmed medical follow-up, by telephone or through written or electronic correspondence with the patients or their primary-care physician.

Statistical analysis {#sec004}
--------------------

Quantitative variables were reported as median and interquartile range (IQR), qualitative variables were reported as figures and percentages. Continuous variables were compared using the Mann- Whitney test, because they had a non-normal distribution. Categorical variables were summarized as percentages and continuous variables as medians and interquartile ranges. Categorical variables were compared using the chi-square test (or Fisher's exact test where necessary). Survival analysis was performed using Kaplan-Meier, and survival curves (showing the survival of patients from diagnosis until the end of the first year) were compared using the log-rank test. Given the limited number of patients in the study, no multivariate logistic regression analyses were performed. A 2-sided P\<0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS software version 18 (SPSS Inc., Chicago, Illinois, USA).

Results {#sec005}
=======

Three hundred and twenty-two patients (16.3%) had definite native valve EFIE. Most patients received AC (183 patients, 56.8%), while ampicillin plus gentamicin (AG) was administered to 73 patients (22.7%), and 66 patients (20.5%) were treated with other options. The patient flowchart is shown in [Fig 1](#pone.0237011.g001){ref-type="fig"}.

![Chart showing patients presenting with definite native valve infective endocarditis according to etiology and treatment (GAMES cohort).](pone.0237011.g001){#pone.0237011.g001}

Among the subset of 183 patients treated with AC, 39 patients were treated exclusively with these antibiotics for four weeks and 70 patients for six weeks. The differences between the short treatment (four weeks) and conventional treatment group (six weeks) are shown in Tables [1](#pone.0237011.t001){ref-type="table"} and [2](#pone.0237011.t002){ref-type="table"}. In terms of baseline conditions, age and comorbidity were similar in patients treated for four weeks and in those treated for six weeks. Chronic liver disease was present in 10.3% (n = 4) of patients receiving short treatment and 10% (n = 7) of patients receiving long treatment. Six patients presented perivalvular abscess and all of these were treated for six weeks (P = 0.072, [Table 2](#pone.0237011.t002){ref-type="table"}). With regard to prognosis related to echocardiographic findings, the presence of perivalvular abscess, valve perforation or a vegetation size greater than 10 mm was associated with an increased risk of recurrence and increased mortality during admission or at one year. Surgery was performed on 14 patients (35.9%) receiving short treatment and on 34 patients (48.6%) receiving long treatment (P = 0.201).

10.1371/journal.pone.0237011.t001

###### Baseline characteristics of patients with native valve E. faecalis infective endocarditis (EFIE) treated with ampicillin plus ceftriaxone according to the duration of antibiotic treatment.

![](pone.0237011.t001){#pone.0237011.t001g}

                                                     4 weeks (n = 39)   6 weeks (N = 70)   P
  -------------------------------------------------- ------------------ ------------------ -------
  Age (years)                                        75 (67--80)        72 (63--78)        0.222
  Male gender                                        26 (66.7)          50 (71.4)          0.604
  Hospital-acquired                                  10 (25.6)          22 (31.4)          0.676
  Non-nosocomial health-care related                 4 (10.2)           10 (14.2)          0.761
  Diabetes mellitus                                  11 (28.2)          20 (28.6)          0.404
  Coronary disease                                   8 (20.5)           22 (31.4)          0.284
  Peripheral arterial disease                        3 (7.6)            8 (11.4)           0.775
  Cerebrovascular disease                            6 (15.4)           5 (7.1)            0.15
  Previous renal failure                             11 (28.2)          17 (24.3)          0.653
  Chronic liver disease                              4 (10.3)           7 (10.0)           0.931
  Injecting drug user                                0                  1 (1.4)            0.648
  Neoplasia                                          9 (23.7)           14 (20.0)          0.655
  Age-adjusted Charlson Comorbidity Index (points)   6 (4--7)           6 (4--8)           0.716

Quantitative variables are reported with median and interquartile range.

10.1371/journal.pone.0237011.t002

###### Clinical presentation an outcome of patients with native valve E. faecalis infective endocarditis (EFIE) treated with ampicillin plus ceftriaxone according to the duration of antibiotic treatment.

![](pone.0237011.t002){#pone.0237011.t002g}

                                                       4 weeks (n = 39)   6 weeks (N = 70)   P
  ---------------------------------------------------- ------------------ ------------------ --------
  Site of infection                                                                          
      Mitral                                           22 (56.4)          48 (68.6)          0.204
      Aortic                                           17 (43.6)          33 (47.1)          0.721
      Tricuspid                                        1 (2.6)            5 (7.1)            0.417
      Pulmonary                                        0                  0                  \-
  Duration of symptoms before diagnosis (days)         7 (1--22)          21 (7--60)         0.002
  Septic shock                                         2 (5.1)            4 (5.7)            0.922
  Persistent bacteremia                                6 (15.4)           10 (14.7)          0.925
  CNS vascular events                                  5 (12.8)           12 (17.1)          0.551
  Embolism                                             8 (20.5)           16 (22.9)          0.717
  Heart failure                                        18 (46.2)          34 (48.6)          0.809
  New or worsening renal insufficiency                 10 (25.6)          20 (28.6)          0.743
  Echocardiographic findings                                                                 
      Vegetation                                       34 (87.1)          62 (88.6)          0.925
      Median size vegetation (IQR)                     12 (8--18)         14 (7--20)         0.471
      Perivalvular abscess                             0                  6 (8.6)            0.060
      Valve perforation or rupture                     4 (10.3)           17 (24.3)          0.060
      Pseudoaneurysm                                   1 (2.6)            3 (4.3)            0.549
      Intracardiac fistula                             0                  0                  \-
  Surgical indication                                  17 (43.6)          45 (64.3)          0.085
  Surgery performed                                    14 (35.9)          34 (48.6)          0.201
  Duration of antibiotic treatment                     32 (28--42)        42 (42--45)        \<0.01
  Treatment with ampicillin (days)                     29 (28--32)        42 (41--45)        \<0.01
  Treatment with ceftriaxone (days)                    29 (28--30)        43 (41--45)        \<0.01
  Hospital stay (days)                                 40 (27--54)        51 (44--66)        0.001
  EFIE relapse[^1^](#t002fn002){ref-type="table-fn"}   2 (5.1)            3 (4.3)            0.833
  In-hospital mortality                                4 (10.3)           8 (11.4)           0.851
  One-year mortality                                   7 (17.9)           15 (21.4)          0.682

CNS: central nervous system. Quantitative variables are reported with median and interquartile range.

^1^See text for relapses.

Outcomes were similar in the two groups: there were no differences regarding the incidence of persistent bacteremia, embolisms, relapses, in-hospital mortality or mortality during the first year ([Table 2](#pone.0237011.t002){ref-type="table"}, [Fig 2](#pone.0237011.g002){ref-type="fig"}). There were five relapses, two in 4wAC group (both during the first six months after treatment) and three in the 6wAC group (both during the first six months after treatment). Two patients had a history of liver cirrhosis (one in each group) and one of them, who suffered two relapses, has already been communicated in a previous publication \[[@pone.0237011.ref017]\]. None of the cases had paravalvular abscesses.

![One-year survival according to duration of the treatment in a series of EFIE.](pone.0237011.g002){#pone.0237011.g002}

Adverse effects attributable to ceftriaxone were leukopenia (two patients, both 6wAC group), glomerulonephritis (one patient, 6wAC group), diarrhea associated with antibiotics without *Clostridiodes difficile* infection (one patient, 4wAC group). Of the 74 patients who received CA for more than 50% of the time but did not meet the criteria for inclusion in the 4- or 6-week treatment groups, 29 patients received at least 4 weeks of treatment. In these patients, mortality during admission was 5.5% (2 patients), mortality during the first year was 22.2% (8 patients) and no cases of recurrence were recorded

Discussion {#sec006}
==========

This is the first cohort study to primarily focus on the prognosis of patients with EFIE treated with a short course of AC. It shows that the prognosis of patients with native valve EFIE treated for 4 weeks with AC is similar to those treated for 6 weeks. However, some differences in the clinical characteristics of patients between the 4-week and 6-week groups may limit the applicability of this result to selected cases.

Both AG and AC have been shown to be synergistic combinations *in vitro* and effective antibiotic treatments *in vivo* for EFIE \[[@pone.0237011.ref001], [@pone.0237011.ref004], [@pone.0237011.ref005], [@pone.0237011.ref019], [@pone.0237011.ref020]\]. However, guidelines recommend different durations for each of these combinations when treating native valve EFIE: four or six weeks for AG and six weeks for AC \[[@pone.0237011.ref008], [@pone.0237011.ref009]\]. The median duration of treatment with AC used in the first two studies to compare the efficacy of AC versus AG was six weeks \[[@pone.0237011.ref004], [@pone.0237011.ref021]\]. As a result, international guidelines incorporated the 6-week protocol as the universal duration for courses of AC to treat both native and prosthetic valve EFIE \[[@pone.0237011.ref008], [@pone.0237011.ref009]\]. The study by Fernandez-Hidalgo et al confirmed that AC given for a median of six weeks was an effective therapy for EFIE and safer than four to six weeks of ampicillin plus gentamicin. However, this study did not clarify whether four weeks of ampicillin plus ceftriaxone would be effective against uncomplicated native valve EFIE \[[@pone.0237011.ref004]\]. A previous single-center study compared 4-week with 6-week treatments for EFIE by analyzing patients treated with AC and AG according to the duration of antibiotic treatment \[[@pone.0237011.ref017]\]. Neither that study nor ours detected higher mortality (either during hospital admission or the first year) associated with short-course treatments. However, in the aforementioned study, relapses were more frequent with short-course treatments (with either AC or AG) when analyzing both native and prosthetic valves. Interestingly, relapses were no higher when analyzing only patients with native valve EFIE who were treated for four weeks. It is also worth noting that the relapse rate in patients who received treatment for four weeks in our study (5%) was similar to the other series of EFIE based on a treatment with AC lasting at least six weeks (3--8%) \[[@pone.0237011.ref001], [@pone.0237011.ref004], [@pone.0237011.ref005], [@pone.0237011.ref021]\].

The propensity of patients with chronic liver disease to develop enterococcal invasive and relapsing infections should be taken into consideration when deciding the appropriate length of EFIE treatment \[[@pone.0237011.ref017], [@pone.0237011.ref022]\]. Among the patients included in this study, only 10% had chronic liver disease, which limits significant conclusions in this regard. Two of the patients who relapsed had chronic liver disease. In any case, considering that these patients have a high surgical risk, it is of paramount importance to try to minimize the risk of relapse, since this could leave surgery as the patient's only recourse. Consequently, we have to express our doubts that a four-week regimen would be recommendable for cirrhotic patients.

Seminal studies that provided evidence for establishing the length of EFIE treatment with beta-lactams plus aminoglycosides showed that longer periods of symptoms have generally been associated to an increased risk of relapse and death \[[@pone.0237011.ref023], [@pone.0237011.ref024]\]. It was suggested that longer illness is due to enterococci that grow relatively slowly and produce dense vegetations which are less accessible to antimicrobial agents \[[@pone.0237011.ref023]\]. Despite the fact that none of studied patients presented symptoms for more than 3 months prior to diagnosis, the duration of symptoms was longer in those who received six weeks compared to those who received four weeks of treatment. It is possible that long treatments were selected for patients with longer duration of symptoms due to its relationship with poor prognoses \[[@pone.0237011.ref023]\]. Therefore, our results may not substantiate the use of short courses in patients with longer duration of symptoms.

All patients with perivalvular abscess received six weeks of AC, which is an expected result. It would be seen as unsafe to select a short course of treatment of either AG or AC in these patients who also had indications for surgical treatment \[[@pone.0237011.ref025]\]. In our series, patients with valve perforation or rupture and those who underwent surgery also tended to receive longer treatment. These clinical differences between the two groups could preclude recommending a short course of AC in patients with some of the above-mentioned characteristics.

We found a significant shortening of the hospital stay in short course treated patients. The saving in patient complications and hospital stay on account of short-course treatment has already been a common goal of various IE studies. \[[@pone.0237011.ref026], [@pone.0237011.ref027]\]. The potential protective effect of shorter courses of beta-lactams, ranging from lower rates of antibiotic-related toxicity to the risk of suffering from *C*. *difficile* infections or for the selection of vancomycin-resistant *E*. *faecium* \[[@pone.0237011.ref028]--[@pone.0237011.ref030]\].

Limitations {#sec007}
-----------

Some limitations of the study should be noted. The main limitation is that it was not a randomized clinical trial, which could have determined that the probability of receiving a short or long treatment depended on certain patient characteristics. Analysis based on \"intention to treat\" could not be done because this variable was not collected in the study. The duration of treatment actually completed by each patient was primarily considered. In addition, most of the institutions participating in the GAMES registry are tertiary university hospitals that receive a substantial number of patients from other centers (most of which do not have facilities for cardiac surgery), which could represent a certain selection bias. And finally, the statistical power of this study is limited due to the low number of patients included. This limitation may have prevented detecting a difference in prognosis in relation to the duration of treatment. These limitations induce caution when drawing conclusions regarding the efficacy of short-course AC treatments. In spite of this limitations, the importance of the pathology studied and the difficulties in carrying out clinical trials in this type of patient allow, in our opinion, to anticipate the possibility of a short treatment for some selected patients.

Conclusions {#sec008}
===========

In conclusion, due to very similar rates of relapse and mortality in patients with native valve EFIE treated with AC for 4 and 6 weeks, this study suggests that a short course of AC might be sufficient to treat native valve EFIE. Due to clinical differences between the two groups studied, a short course of antibiotics cannot be recommended for patients presenting with longer duration of symptoms or perivalvular abscess. Further research is required to validate these results as well as to elucidate whether short-course treatments should be recommended to treat all native valve EFIE, or only to treat selected patients with specific features that present a more favorable prognosis which is still to be defined. This study could be the rationale for performing a randomized clinical trial in non-complicated native valve EFIE.
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Dear Dr. Ramos,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Cécile Oury

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please provide the full names of the Institutional Review Boards s that approved the study in your manuscript.

3\. Please specify in your ethics statement whether participant consent was written or verbal. If verbal, please also specify: 1) whether the ethics committee approved the verbal consent procedure, 2) why written consent could not be obtained, and 3) how verbal consent was recorded." Do not ping with follow up unless there are questions

4\. Thank you for stating the following in the Acknowledgments Section of your manuscript:

\'This work was supported in part by the "Fondo de Investigaciones Sanitarias" (FIS)

grant 17/01251 from the "Instituto de Salud Carlos III", Madrid, Spain awarded to

JMM. JMM received a personal 80:20 research grant from the Institut d'Investigacions

Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017--19. JMP was

member of the Endocarditis Team of the Hospital Clinic of Barcelona, Spain when this

project was approved by the GAMES Steering Committee.\'

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\'The funders had no role in study design, data collection and analysis, decision to

publish, or preparation of the manuscript.\'

5\. Thank you for stating the following in the Competing Interests section:

\'Dr. Ramos-Martínez declares personal fees from Merck, Astellas and Pfizer, outside

the submitted work. Dr. Ojeda-Burgos reports personal fees from Merck, personal fees

from Janssen Cilag, personal fees from Gilead, outside the submitted work. Dr. Miro

reports grants and personal fees from AbbVie, Bristol-Myers Squibb, Contrafect,

Genentech, Jansen, Medtronic, Merck, Novartis, Gilead Sciences, and ViiV Healthcare,

outside the submitted work. Dr. Juan M Pericas. Dr. Ana Fernández-Cruz, Dr. Patricia

Muñoz, Dr. Maricela Valerio, Dr. Martha Kestler, Dr. Miguel Montejo, Dr. Mª Carmen

Fariñas, Dr. Dolores Sousa, Dr. Fernando Domínguez, Dr. Antonio Plata and Dr. Laura

Vidal have nothing to disclouse\'

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors [http://journals.plos.org/plosone/s/competing-interests](about:blank)).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [http://journals.plos.org/plosone/s/competing-interests](about:blank)

6\. Please amend the manuscript submission data (via Edit Submission) to include author Guillermo Ojeda-Burgos MD PhD

Additional Editor Comments (if provided):

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Dear authors,

Your work addresses an important clinical issue with regard to treating patients with NVEFIE. Interesting work.

Major issues:

1\. Statistical issue: p8, 202-204. It is stated that continous varibales will be reported as a median with IQR and that a student\'s t-test will be used to compare these values. If you report values as a median with IQR, it means that your data was not normally distributed. Did you check if the continous variables had a normal distribution? In that case, it is not correct to use a student\'s t-test and a non-parametric test should be used.

2\. Statistical issue: p8, 204. The aim of this study is to test whether the clinical outcome of patients that received AC for 4 weeks is similar to those that received AC for 6 weeks. Student t-tests are made to test if there is a significant difference, not to test equivalance. Did you perform an equivalence test or can this be conducted?

3\. p3, 100-101. In the abstract you mention that patients that received AC for 4 weeks had a longer duration of symptoms (21 days) than patients thet received AC for 6 weeks (7 days). In table 1, the values are the opposite. Is this a mistake? Should be corrected, because it is concluded that treatment with AC for 4 weeks may be considered in patients with a shorter duration of symptoms.

Minor issues:

4\. Does severity of symptoms correlate with a worse outcome? For example, perivalvular abscesses, vegetation size, valve perforation, \...

5\. Data represented in table 1 will be more clear if this table is divided in to two tables: one with the baseline characteristics and another one with the data on outcome.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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14th June 2020

Dear Editor

Thank you for revising our article entitled: \"Four weeks versus six weeks of ampicillin plus ceftriaxone in Enterococcus faecalis native valve endocarditis: A prospective cohort study" (PONE-D-20-05909).

Please find below the responses to the suggestions and recommendations made by the reviewer. We hope that the revised version satisfies their concerns. To highlight the changes in the manuscript they have been written in blue. In addition, while revising the manuscript we have also taken the opportunity to correct a few grammatical and typographic errors which in no way affect the scientific content of the article.

Journal Requirements

We have tried to all meet PLOS ONE\'s requirements. The online system on the manuscript submission has not allowed us to enter the funding information correctly. Please update our funding statement to include: \'This work was supported in part by the "Fondo de Investigaciones Sanitarias" (FIS) grant 17/01251 from the "Instituto de Salud Carlos III", Madrid, Spain awarded to JMM. JMM received a personal 80:20 research grant from the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017--19. JMP was member of the Endocarditis Team of the Hospital Clinic of Barcelona, Spain when this project was approved by the GAMES Steering Committee.\'

All authors declare no potentially competing interests that occurred within 5 years of conducting the research under consideration nor preparing the article for publication.

Reviewer

1\. Statistical issue: p8, 202-204. It is stated that continuous variables will be reported as a median with IQR and that a student\'s t-test will be used to compare these values. If you report values as a median with IQR, it means that your data was not normally distributed. Did you check if the continuous variables had a normal distribution? In that case, it is not correct to use a student\'s t-test and a non-parametric test should be used.

We appreciate the reviewer\'s comment. The quantitative variables studied did not present a normal distribution, so it was necessary to use the Mann-Whitney test. Accordingly, the paragraph referring to statistical analysis has been modified.

2\. Statistical issue: p8, 204. The aim of this study is to test whether the clinical outcome of patients that received AC for 4 weeks is similar to those that received AC for 6 weeks. Student t-tests are made to test if there is a significant difference, not to test equivalence. Did you perform an equivalence test or can this be conducted?

In fact, we did not use the Student t-tests to ascertain whether there was a difference between the two groups. What we intended to do was to check whether the prognosis of the patients (assessed by the rate of disease recurrence or mortality) was similar with both therapeutic regimes. We considered that the most appropriate way to check that the two regimes were not different in our patients was to use a qualitative test such as Fisher\'s.

3\. p3, 100-101. In the abstract you mention that patients that received AC for 4 weeks had a longer duration of symptoms (21 days) than patients that received AC for 6 weeks (7 days). In table 1, the values are the opposite. Is this a mistake? Should be corrected, because it is concluded that treatment with AC for 4 weeks may be considered in patients with a shorter duration of symptoms.

In effect, it is a mistake. Patients who were treated for 4 weeks had a shorter duration of symptoms before admission. As noted in previous research, it has traditionally been considered that treatment of this infection should be at least 6 weeks in patients with longer duration of symptoms or with perivalvular abscess

4\. Does severity of symptoms correlate with a worse outcome? For example, perivalvular abscesses, vegetation size, valve perforation, \...

A sentence has been added about the absence of influence on the prognosis (infection recurrence and mortality) of echocardiography findings as the presence of perivalvular abscess, valve perforation or a vegetation size larger than 10 mm

5\. Data represented in table 1 will be more clear if this table is divided in to two tables: one with the baseline characteristics and another one with the data on outcome.

Table 1 has been broken down into 2 tables on the advice of the reviewer

###### 

Submitted filename: Response to reviewers - PONE-D-20-05909R1.docx

###### 

Click here for additional data file.
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Dear Dr. Ramos,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Cécile Oury

Academic Editor

PLOS ONE
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Dear Dr. Ramos-Martínez:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Cécile Oury

Academic Editor

PLOS ONE
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